When to Start Tenofovir in Chronic Hepatitis B
Tenofovir disoproxil fumarate (TDF) should be initiated in chronic hepatitis B patients based on specific clinical criteria: presence of cirrhosis or advanced fibrosis, elevated ALT with HBV DNA >2000 IU/mL, or age >30 years with detectable HBV DNA regardless of ALT levels. 1
Treatment Indications by Clinical Scenario
Patients WITH Cirrhosis or Advanced Fibrosis
- Start TDF immediately if HBV DNA is detectable, regardless of ALT level 1
- This is non-negotiable due to high risk of hepatic decompensation and hepatocellular carcinoma
- The FDA label confirms TDF is indicated for chronic HBV in adults and pediatric patients ≥12 years 2
Patients WITHOUT Cirrhosis
HBeAg-Positive Patients:
- Start TDF when HBV DNA >2000 IU/mL AND ALT is elevated (>2x upper limit of normal for men, >1.5x for women) 1
- Consider treatment if age >30 years with HBV DNA 2000-20,000 IU/mL even with normal ALT 3
HBeAg-Negative Patients:
- Start TDF when HBV DNA >2000 IU/mL AND ALT is elevated 1, 3
- Emerging evidence supports earlier treatment: Recent trial data shows that starting TDF in patients aged 40-80 years with HBV DNA 4-8 log10 IU/mL and normal/mildly elevated ALT significantly reduced serious liver events (hazard ratio 0.21, p=0.027) 4
Age-Based Considerations
The 2025 EASL guidelines and emerging Asian guidelines advocate for treatment in patients >30 years old with detectable HBV DNA (>2000 IU/mL) regardless of ALT, based on recognition that significant liver disease can progress despite normal transaminases 5, 4
Special Populations Requiring Immediate Prophylaxis
Immunosuppression/Chemotherapy
- Start TDF prophylactically BEFORE immunosuppression in all HBsAg-positive patients 1
- Continue for at least 6-12 months after immunosuppression ends
- For B-cell depleting therapy (rituximab): extend prophylaxis to at least 18 months post-chemotherapy due to late reactivation risk 1
Liver Transplantation
- Start TDF (or entecavir/TAF) immediately as part of HBV recurrence prophylaxis, typically combined with hepatitis B immunoglobulin 1
Dosing Specifications
- Standard dose: 300 mg orally once daily 2
- Renal adjustment required: If creatinine clearance <50 mL/min, adjust dosing interval per FDA label 2
- Pediatric (≥12 years, ≥35 kg): 300 mg once daily 2
- Weight-based dosing for children 17-35 kg available in tablet formulations 2
Pre-Treatment Testing Requirements
Before initiating TDF, you must:
- Test for HIV-1 infection (TDF alone is inadequate for HIV treatment and risks resistance) 2
- Assess baseline: serum creatinine, estimated creatinine clearance, urine glucose, urine protein 2
- In patients with chronic kidney disease: also check serum phosphorus 2
Critical Safety Monitoring
- Renal function: Check creatinine, phosphorus, urine glucose/protein at baseline and at least annually (more frequently if high-risk) 3, 2
- Bone density: Consider monitoring in patients with osteoporosis risk factors, though not routinely required 3
- Post-discontinuation: If TDF is ever stopped, monitor closely for at least several months with both clinical and laboratory follow-up, as severe acute HBV exacerbations can occur 2
Common Pitfalls to Avoid
- Don't wait for ALT elevation in cirrhotic patients - any detectable HBV DNA warrants treatment
- Don't use TDF monotherapy if HIV co-infection exists - this creates HIV resistance risk 2
- Don't forget renal dose adjustment - significant drug accumulation occurs with creatinine clearance <50 mL/min 2
- Don't stop monitoring after discontinuation - hepatitis flares can be severe and life-threatening 2
Treatment Efficacy Expectations
- Viral suppression: 93-98% achieve HBV DNA <400 copies/mL by week 48 6
- Long-term outcomes: 99-100% maintain viral suppression through 10 years with excellent safety profile 7
- No resistance: Zero documented TDF resistance through 10 years of treatment 8, 7
- HBsAg loss: Occurs in 3-27% depending on HBeAg status and treatment duration 6, 7